[vc_row][vc_column][vc_column_text]

Chronic Histiocystics Intervillositis (CHI) Causes

How common is CHI?

It is considered a rare placental inflammatory disease. Currently diagnosed in approximately 1% of spontaneous abortions/miscarriages and in less than 1% of placentas in 2nd and 3rd trimester. It is frequently missed as a diagnosis with a high recurrence risk as placentas may not always be analysed after an event. The same applies for cases of fetal growth restriction with live birth outcome. Furthermore, there is still lack of awareness among Pathologists themselves who are still being educated on how to recognise it when analysing the placenta.

What Causes CHI?

At this current time the trigger is unknown, possible immunologic origin, most likely alloimmune due to the nature of the disorder. CHI might also be confused with infectious placental lesions observed in; malaria, listeriosis, tularemia, CMV, herpes, and polymorphous inflammatory infiltrate.

Women with this problem make antibodies to DNA components in the embryo, or in the pregnancy tissue that surrounds it. These antibodies form first in the blood and later graduate to the lymphatic system and the tissue. After repeated losses, antibodies to DNA components can develop into antibodies that occupy organs such as the uterus, and cause local inflammation that may contribute to further pregnancy losses. For CHI sufferers this manifestation of where antibodies to the baby and components of placental DNA cause inflammation in the placenta.

There is also an association with an abnormal thrombophilia most commonly with Factor V Leiden.

[/vc_column_text][/vc_column][/vc_row]

Clinic Fees

  • Initial consultation – £350 (a deductible £100 deposit is required to secure this appointment)
  • Follow up consultation – £200
  • Immune tests – tests range from £150 to £700 each
  • Wellbeing tests – tests range from £60 to £155 each
  • Hormonal tests – tests range from £87 to £105 each
  • Non-invasive Fetal DNA testing – £450
  • Initial scan – £235
  • 3D saline scan – £450
  • HyFosy – £475
  • 3D saline scan + Hyfosy – £625
  • Early pregnancy scans (includes consultation) – £290
  • Nuchal scan (includes blood tests) – £360
  • Anomaly scan – £360
  • Growth scans package (28, 32 and 36 weeks) – £760

    Fetal Medicine scan packages are available on request.
  • Manual Vacuum Aspiration (MVA) – from £1893
  • Hysteroscopy – from £1300
  • Initial consultation –  £285
  • Nurse consultation – £200
  • IVF cycle –  From £3950 (excludes initial and nurse consultations medications,  pre-IVF investigation tests)

    IVF packages are available on request.
  • Initial consultation – £285
  • Nurse consultation – £200
  • IUI cycle –  From £1200 (excludes initial and nurse consultations medications,  pre-IUI investigation tests)

    IUI packages are available on request
  • Sperm DNA Integrity – £490
  • Semen Analysis – £225

Thank You!

Thank you for reaching out to us and completing the enquiry form on our website. We appreciate your interest in our services and understand the importance of this journey for you.

Our team is dedicated to providing you with the support and care you need. One of our specialists will review your enquiry and get back to you to discuss your needs and answer any questions you may have.

We look forward to assisting you and being a part of your journey towards building your family.

Professor Hassan Shehata

Professor Hassan Shehata is a Consultant Obstetrician and Gynaecologist, specialised in Maternal Medicine at Epsom and St. Helier University Hospitals NHS Trust. With an extensive CV, he has contributed his expertise to various hospitals within the UK, building a wealth of experience in obstetrics and gynaecology.

In addition to his diverse clinical background, Professor Shehata is the CEO and Medical Director of the CRP Clinic. He has a wealth of global health contributions including reducing medicalisation of Female Genital Mutilation. He has dedicated his professional life to investigating and treating recurrent miscarriages and addressing challenges associated with failed IVF attempts.